Comparison of Tablet and Disk Diffusion Methods for Fluconazole and Voriconazole In Vitro Activity Testing Against Clinical Yeast Isolates

References

• Garcia-Ruiz JC, Amutio E, Pont6n J. Invasive fungal infection in immunocompromised patients. Rev Iberoam Micol 2004; 21: 55–62.
   Google Scholar
• Pontein J, Michel R, Clemonds KV, et al. Emerging pathogens. Med Mycol 2000; 38; suppl 1: 225-236.
   Google Scholar
• Giusiano G, Mangiaterra M, Rojas F, Gãmez V. Azole resistance in neonatal intensive care units. J Chemother 2005; 17: 347–350.
   PubMed Web of Science ®Google Scholar
• Carrillo-Munoz AJ, Quind6s G, L6pez-Ribot JL. Current developments in antifungal agents. Curr Med Chem Anti Infect Agents 2004; 3: 297–323.
   Google Scholar
• Odds FC. Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? Rev Iberoam Micol 1997; 14: 83–84.
   PubMedGoogle Scholar
• Espinel-Ingroff A, Warnock DW, Vazquez JA, Arthimgton-Skaggs BA. In vitro antifungal susceptibility meth-ods and clinical implications of antifungal resistance. Med Mycol 2000; 38: 293–304.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive break-points. J Clin Microbiol 2006; 44: 819–826.
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correla-tion data for fluconazole, itraconazole, and Candida infec-tions. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar
• Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-160.1°
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition. NCCLS document M27-A2. 2002.
   Google Scholar
• Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing suscep-tibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884–3889.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa., 2004.
   Google Scholar
• Carrillo-Munoz AJ, Cárdenes CD, Carrillo-Orive B, Rodriguez V, del Valle 0, Casals J, Quind6s G. Antifungal activity of voriconazole against dermatophytes and Scopulariopsis brevicaulis determined by an agar diffusion method (Neo-Sensitabsm). Rev Iberoam Micol 2005; 22: 108–111.
   Google Scholar
• Rosco Diagnostica AG. Users' guide Neo-SensitabsTh susceptibility testing. 18th edition. 2005/2006.
   Google Scholar
• Casals JB. Tablet sensitivity testing on pathogenic fungi. J Clin Pathol 1979; 32: 719–722.
   PubMed Web of Science ®Google Scholar
• Carrillo-Munoz AJ, Abarca L, Quind6s G, et al. Multicenter evaluation of Neo-Sensitabs, a standardized diffu-sion method for yeast susceptibility testing. Rev Iberoam Micol 1999; 16: 97–101.
   Google Scholar
• Carrillo-Munoz AJ, Brie) S, Alonso R, del Valle 0, Santos P, Quind6s G. Ciclopiroxolamine: in vitro antifungal activity against clinical yeasts isolates. Int J Antimicrob Agents 2002; 20: 375–379.
   Google Scholar
• Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by stan-dardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848–5859.
   Google Scholar
• Testore GP, Dori L, Buonomini AR, et al. In vitro flu-conazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. Diagn Microbiol Infect Dis 2004; 50: 187–192.
   PubMed Web of Science ®Google Scholar
• Quind6s G, Abarca L, Carrillo-Munoz AJ, et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol 1999; 16: 102-105.
   Google Scholar
• Cantem E, Peman J, Carrillo-Munoz A, Orero A, Ubeda P, Viudes A, Gobernado M. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. Clin Microbiol 1999; 37: 2197–2200.
   Google Scholar
• Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffu-sion methods for determining susceptibilities of 235 blood-stream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003; 41: 1875–1880.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL. Correlation between the procedure for antifungal susceptibility testing for Can dida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 2005; 11: 486–492.
   Google Scholar